Answers are grounded in this paper and cite their sources.
Objectives: To evaluate the results of treatment of patients with chronic hepatitis C with Sofosbuvir/Velpatasvir regimen and adverse effects of the regimen. Subjects and methods: A cross sectional descriptive study with follow up 12 weeks after the end of treatment. 46 patients confirmed diagnosis of chronic hepatitis C according to 2016 Guidelines for diagnosis and treatment of hepatitis C virus of Ministry of Health. They received Sofosbuvir 400mg/Velpatasvir 100mg combination once daily for 12 weeks. Patients were followed up six months after the start of therapy. Hepatitis C viral load was assessed at baseline, at week 4 and after 24 weeks following the start of the treatment. Result: 34 patients without cirrhosis (97.1%) and 10 patients with compensated cirrhosis (90.9%) achieved RVR. A total of 100% of patients without cirrhosis and 90.9% of patients with compensated cirrhosis achieved SVR 12 weeks after the end of therapy. Patients with compensated cirrhosis experienced more adverses events (45.5%) than patients without cirrhosis (8.57%). None of the patients without cirrhosis or with compensated cirrhosis experienced any serious adverse event. A few patients complained about some symtoms such as fatigue (6/46, 13.0%), ichy/rash (2/46, 4.3%), insomnia (2/46, 4.3%), jaundice (1/46, 2.1%) - which appeared after received Sofosbuvir/Velpatasvir therapy. Most certain laboratoty abnormalities were seen in patients with compensated cirrhosis. Conclusion: The therapy of sofusbuvir/velpatasvir combination daily for 12 weeks is safe and efficacious in hepatitis C patients without cirrhosis or with compensated cirrhosis, irrespective of the genotype.
No takes yet. Share an insight, caveat, or question.
Lien et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: